kidney medullary carcinoma | ClinicalTrials HQ

View definition

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors	Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, bladder adenocarcinoma, bladder clear cell adenocarcinoma, bladder mixed adenocarcinoma, bladder squamous cell carcinoma, bladder urachal adenocarcinoma, carcinoma, chromophobe renal cell carcinoma, epithelial neoplasm, infiltrating bladder urothelial carcinoma, kidney cancer, kidney disorder, kidney medullary carcinoma, large cell neuroendocrine carcinoma, male reproductive organ cancer, male reproductive system disorder, malignant testicular Leydig cell tumor, neoplasm, papillary renal cell carcinoma, penile disorder, penile neoplasm, prostate cancer, prostate disorder, renal cell carcinoma, sarcomatoid renal cell carcinoma, transitional cell carcinoma, urethra clear cell adenocarcinoma, urethra neoplasm, urethral disorder, urinary bladder disorder, urinary bladder neoplasm, urinary bladder small cell neuroendocrine carcinoma, urinary system disorder	Recruiting	Phase 2	2026-10-09		NCT03866382
Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla	Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, kidney medullary carcinoma, neoplasm	Active, not recruiting	Phase 2	2026-10-07		NCT05347212
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study	Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, chromophobe renal cell carcinoma, clear cell renal carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, kidney medullary carcinoma, neoplasm, papillary renal cell carcinoma, renal cell carcinoma, urinary system disorder	Active, not recruiting	Phase 2	2026-09-28		NCT04071223
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors	Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, bladder squamous cell carcinoma, bladder transitional cell carcinoma, carcinoma, clear cell renal carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, kidney medullary carcinoma, male reproductive organ cancer, male reproductive system disorder, neoplasm, penile carcinoma, penile disorder, penile neoplasm, renal cell carcinoma, renal pelvis urothelial carcinoma, sarcomatoid renal cell carcinoma, squamous cell carcinoma of penis, ureter cancer, ureter transitional cell carcinoma, ureteral disorder, urethra neoplasm, urethra transitional cell carcinoma, urethral disorder, urinary bladder disorder, urinary bladder neoplasm, urinary bladder small cell neuroendocrine carcinoma, urinary system disorder	Active, not recruiting	Phase 1	2026-09-10		NCT02496208
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...	Neoplasms by Histologic Type, bladder squamous cell carcinoma, carcinoma, epithelial neoplasm, kidney medullary carcinoma, neoplasm, squamous cell carcinoma of penis, transitional cell carcinoma	Recruiting	Phase 2	2026-08-13		NCT06161532
Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies	Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, kidney medullary carcinoma, neoplasm, sarcoma	Active, not recruiting	Phase 2	2026-08-06		NCT06444880
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors	Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, atypical teratoid rhabdoid tumor, chordoma, kidney medullary carcinoma, mixed neoplasm, neoplasm, poorly differentiated chordoma, rhabdoid tumor, sarcoma	Active, not recruiting	Phase 1 / Phase 2	2026-07-14		NCT05286801
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, collecting duct carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, kidney medullary carcinoma, neoplasm, renal cell carcinoma, urinary system disorder	Recruiting	Phase 2	2025-09-09		NCT06302569